Track record · closed signal

Doximity, Inc. (DOCS) — closed signal from December 22, 2025

Partial Published before the outcome was known, scored automatically when the window closed on March 22, 2026.

Predicted vs. what happened

DOCS price · publication thesis → realized outcomesplit-adjusted

$43.50 – $45.00Entry zone — fair-value band

$44.66Published — price the day we called it

$57.16Target — the price the thesis aimed for

$46.75Peak — highest point inside the window, not a realized return

$24.41Window close — end-of-window price, context only

What happened

Partial

Reached 17% of the predicted growth at its peak, without hitting the target.

Peak price

$46.75

peak on January 6, 2026 — not a realized return

Peak gain

+4.7%

peak, from the publication price

Window close

$24.41

end-of-window price, context only

Days to target

—

Window

December 22, 2025 – March 22, 2026

The thesis — published December 22, 2025

Predicted growth

+28%

over the measurement window

Target price

$57.16

the price the thesis aimed for

Entry zone

$43.50 – $45.00

the fair-value band we waited for

Price at publication

$44.66

published December 22, 2025

Confidence

82%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

The stock looks primed for a rebound: readings show it's been oversold but momentum is starting to turn and investor sentiment is very high (98). Bank of America reaffirmed Buy and pointed to AI workflow tools and shifting pharma ad budgets as reasons for upside. Because the improvement is still early and price signals conflict with sentiment, wait for quick confirmation and keep position size small for a 0-3 month swing.

Primary drivers

Stock looks oversold and momentum is beginning to turn, which can spark a bounce
Analyst notes point to AI workflow tools and rising pharma ad budgets aiding growth
Very strong investor sentiment can speed a quick rally if price holds support
A narrow buy range helps limit losses if the rebound reverses

How it played out

DOCS: the thesis did not reach its target

Lyra published DOCS at 44.66 on December 22, 2025 for a short-term swing through March 22, 2026. The thesis expected 28% growth to 57.16. It pointed to an oversold setup, early momentum improvement, very strong investor sentiment at 98, Bank of America Buy support, artificial intelligence workflow tools, and shifting pharma ad budgets.

Inside the window, DOCS peaked at 46.75 on January 6, 2026, a 4.7% gain. It stayed below the 57.16 target and never reached it. By the end of the window, the stock was at 24.41. The published rebound thesis missed.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All DOCS signals